Calidi Biotherapeutics Inc(CLDI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 5:18 AM ET (Korea 9/29 18:18)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -54.07 | Insider Own | 0.87% | Shs Outstand | 2.6M | Perf Week | -3.8% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.6M | Perf Month | -17.69% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 1.27% | Short Float | 8.9% | Perf Quarter | -58.49% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | -3.73% | Short Ratio | 0.77 | Perf Half Y | -75.3% |
| Sales | 0.00B | P/B | 0.71 | EPS next 5Y | - | ROA | -283.36% | Short Interest | 0.23M | Perf YTD | -94.28% |
| Book/sh | 1.5 | P/C | 0.92 | EPS past 3/5Y | 74.5% - | ROE | -957.93% | 52W High | -96.16% ($27.84) | Perf Year | -95.74% |
| Cash/sh | 1.17 | P/FCF | - | Sales past 3/5Y | - | ROIC | -601.56% | 52W Low | 1.9% ($1.05) | Perf 3Y | -99.98% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 53.95% | Gross Margin | - | Volatility(W/M) | 9.7% 7.95% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.68 | EPS Q/Q | 90.76% | Profit Margin | - | RSI (14) | 35.47 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.68 | Sales Q/Q | - | SMA20 | -13.18% ($1.23) | Beta | 1.32 | Target Price | $1920 |
| Payout | - | Debt/Eq | 0.62 | Earnings | 2026/8/13 | SMA50 | -25.37% ($1.43) | Rel Volume | 0.52 | Prev Close | $1.13 |
| Employees | 29 | LT Debt/Eq | 0.25 | EPS/Sales Surpr. | - | SMA200 | -84.37% ($6.85) | Avg Volume(3M) | 0.30M | Price | $1.07 |
| IPO | 2021/11/1 | Option/Short | No/Yes | Trades | 308 | Volume | 154,902 | Change | -5.31% |
🧬 A clinical-stage biotech company developing allogeneic stem cell and oncolytic virus platforms for cancer immunotherapy. The company holds multiple pipelines aimed at treating solid tumors and gliomas.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual That is 52% of its average volume.
CLDI has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -100.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #559 of 592 in the industry
Based on market cap of $4M.
HCWB#557 HCW Biologics Inc $4M PER - 
CVKD#558 Cadrenal Therapeutics Inc $4M PER - CLDI#559 Calidi Biotherapeutics Inc $4M PER - 
ELAB#560 PMGC Holdings Inc $4M PER - 
MBIO#561 Mustang Bio Inc $4M PER - 
FAQ
What kind of company is CLDI?
CLDI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CLDI?
The market cap of CLDI is approximately $4M, ranking 5,737 within its sector.
What is the 52-week high and low for CLDI?
CLDI has recorded a 52-week high of $27.84 and a low of $1.05.
